Biomaterials Impact Factor

This is a strong number in a field where citation density is already healthy. The five-year JIF of 14 running above the two-year JIF suggests something important: Biomaterials papers often stay relevant after the short citation window that dominates more trend-driven materials publishing. That matters for authors because the journal rewards studies that become reference points for material-biology decisions, not only papers with a high-performing material in one assay.

The cited half-life of 9.0 years supports that interpretation. Papers in this journal frequently keep mattering because they become reference points for interface mechanisms, scaffold logic, biomaterial design choices, implant performance, and translational benchmarks.

The JIF without self-cites is 12.6, almost unchanged from the headline JIF. That tells you the journal's citation performance is not depending on aggressive internal citation behavior.

For target selection, the practical reading is strict: a 13.6 JIF confirms that Biomaterials is a high-authority specialty journal, but it also raises the evidence bar. A manuscript that only proves synthesis, morphology, mechanical strength, or release behavior is not automatically a Biomaterials fit. The paper needs to show how the material changes a biological interaction, tissue response, therapeutic or diagnostic procedure, or host-interface outcome.

The common misunderstanding is that a strong material plus a little biology should be enough. It usually is not.

Biomaterials does not reward papers simply because they involve cells, tissue, or an implant context. It rewards manuscripts where:

• the material design is central

• the biological mechanism is legible

• the evidence chain supports the application claim

That is why the journal's citation performance remains strong. It publishes papers that other authors keep returning to when they need a real biomaterials precedent, not just a clever materials result with biomedical framing.

The current JCR row is the authoritative impact factor on this page. For the longer directional picture, the table below uses the open Scopus-based impact score series as a trend proxy.

The open citation line is up from 9.49 in 2014 to 13.17 in 2024, and it ticked up from 13.06 in 2023 to 13.17 in 2024 after a modest normalization from the 2021 peak. That is a healthy signal for a mature specialty journal. It suggests the journal is not living off old prestige alone. It is still publishing papers that the field actively reuses.

The line also helps explain why the journal stays commercially important for Manusights. Authors aiming here are rarely looking for a soft landing. They are usually trying to place a serious biomaterials manuscript and need fit guidance before they lose months at triage.

In our review of Biomaterials manuscripts, the common problem is not weak materials science. It is a gap between the application language and the biological evidence. The title promises a translational biomaterial, the abstract promises a therapeutic or diagnostic consequence, and the figures often prove a material property. The editor-facing question is whether those pieces form one evidence chain before the paper asks reviewers for months of attention.

Biomaterials pattern: the first figure proves the material, not the biology. This happens when Figure 1 is synthesis, morphology, chemistry, mechanics, or release behavior, while the biological response arrives as a later supporting panel. The manuscript component to inspect is the opening figure sequence. A stronger Biomaterials package shows early why the material choice changes cell behavior, tissue response, host interaction, drug delivery, immune state, or diagnostic performance.

Biomaterials pattern: the comparator is too convenient. Many borderline drafts compare against a blank scaffold, free drug, unmodified polymer, or weak commercial material. That can prove improvement, but it may not prove that the new biomaterial is competitive. The comparator table should make the benchmark credible before the manuscript leans on the 13.6 JIF target.

Biomaterials pattern: mechanism language outruns the model. Authors often write as if a material explains regeneration, immunomodulation, tumor response, wound healing, osteogenesis, angiogenesis, or antibacterial behavior, but the actual model only shows a narrow in vitro outcome. Biomaterials can publish focused work, but the mechanism, model, and application claim need to stay proportionate.

Biomaterials pattern: the graphical abstract hides the evidence chain. Elsevier requires a graphical abstract for Biomaterials submissions. If that figure only shows material fabrication plus an endpoint result, it can expose the same weakness as the paper itself. The graphical abstract should make the path from material design to biological response visible without overselling clinical translation.

SciRev community reports reinforce the practical point: once the manuscript goes out, the review can be serious and slow. That makes it worth fixing the evidence chain before submission rather than after a long review cycle.

The current 13.6 JIF is strong, but authors still need to check the mechanics before choosing Biomaterials.

Use this page when the decision is whether the metric justifies aiming at Biomaterials before you spend time in Editorial Manager. It is not a replacement for checking the live Elsevier author guide.

Three failure patterns show up repeatedly before submission.

The biology is too thin for the claim. Strong characterization plus one viability assay or a single microscopy panel is not usually enough to carry a translational or interface-performance claim here.

The paper reports better outcomes without a mechanistic bridge. Editors want to see why the material causes the biological effect, not just that the effect exists.

The comparator is too weak. Many borderline submissions test a new material against no serious benchmark, which makes the performance claim hard to trust.

If that describes the draft, a Biomaterials submission readiness check is usually more informative than polishing the abstract again.

It does not tell you:

• whether the validation model is strong enough for the claimed application

• whether the biological evidence is proportionate to the translational language

• whether the material-biology connection is mechanistic or merely descriptive

• whether Acta Biomaterialia, Bioactive Materials, or a broader materials venue is the cleaner fit

Those are the real reasons papers get desk-rejected.